Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus
Objective Hydroxychloroquine (HCQ) is a mainstay of therapy in the treatment of SLE. The effect of HCQ on platelets and vascular health is uncertain. We investigated the relationship between HCQ use and dose with platelet activity, platelet transcriptomics and vascular health in patients with SLE.Me...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-09-01
|
Series: | Lupus Science and Medicine |
Online Access: | https://lupus.bmj.com/content/8/1/e000475.full |